ZAP Surgical and Swiss Neuro Radiosurgery Center Announce Imminent Installation of New Gyroscopic Radiosurgery Platform for Treating Brain Tumors

ZAP Surgical Systems, Inc. today announced the imminent installation of its advanced ZAP-X® Gyroscopic Radiosurgery® platform at the Swiss Neuro Radiosurgery Center (SNRC), an organization within the Swiss Clinical Neuroscience Institute (SCNSI) in Zurich, Switzerland.

Stereotactic radiosurgery (SRS) is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors, as well as select intracranial functional and vascular disorders. Considered an alternative to surgery for these indications, SRS is a non-invasive outpatient procedure that often provides equivalent to superior outcomes, yet no surgical incision, and little to no recovery period.

The ZAP-X system is recognized for using gyroscopic motion to direct radiosurgical beams from a multitude of unique angles which precisely concentrate radiation to the tumor target, resulting in significantly less healthy brain tissue exposure than those of multi-purpose radiation delivery systems. This unique approach supports the clinical objective of protecting healthy brain tissue and neuro-cognitive function.

ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, thus eliminating the significant costs to license, secure and regularly replace live radioactive isotopes.

“The local core-team consisting of neurosurgeon Christoph Weber, MD, radiation oncologist Cristina Picardi, MD, and myself are looking forward to putting Switzerland’s first ZAP-X into operation,” said Andreas Mack, PHD, founder and chief executive officer of SNRC.

“With an interdisciplinary focus on neuro-radiosurgical treatments, the project is a cooperative effort including the Klinik Hirslanden Institute for Radiotherapy, the Center for Endoscopic and Minimally Invasive Neurosurgery, namely Robert Reisch, MD, and Nikolai Hopf, MD, and the Center for Micro Neurosurgery, namely Ralf Kockro, MD,” added Mack. “Additionally, SNRC is scientifically advised by the clinical team at the University Hospital of Basel, Department of Neurosurgery, namely Luigi Mariani, MD, Raphael Guzman, MD, and Ethan Taub, MD.”

ZAP Surgical is excited to partner with SNRC to bring world-class radiosurgery to Zurich and the surrounding communities,” said Hakan Baraner, ZAP Surgical’s Senior Vice President for Europe, Middle East, and Africa. “We believe SNRC’s ZAP-X program will serve as an example to many other medical centers, both locally and globally.”

SNRC estimates first patient treatments with ZAP-X will commence in the summer of 2021.

 

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.